lower levels of triglycerides and lower instances of cardiovascular disease. Humans with elevated levels of apoC-III have increased dyslipidemia associated with multiple metabolic abnormalities, such as insulin resistance and/or metabolic syndrome. In addition, the prevalence of type 2 diabetes is increased in patients with elevated triglycerides.Conference CallAt 08:30 a.m. Eastern Time Monday, Sept. 23, 2013, Isis will conduct a live webcast and slide presentation conference call to discuss the positive Phase 2 data presented today. Interested parties may listen to the call by dialing 866-652-5200, or access the webcast with or without audio at www.isispharm.com
. A webcast replay will be available for a limited time at the same address.
ABOUT ISIS PHARMACEUTICALS, INC.Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 30 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer. Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO™, in the United States for the treatment of patients with HoFH. Isis' patents provide strong and extensive protection for its drugs and technology. Additional information about Isis is available at www.isispharm.com.
ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENTThis press release includes forward-looking statements regarding the discovery, development, and potential of drugs for cardiovascular diseases, and the development, activity, therapeutic potential and safety of ISIS-APOCIIIRx. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, is a forwa
Page: 1 2 3 4 5 6 Related medicine technology :1
|SOURCE Isis Pharmaceuticals, Inc.|
Copyright©2012 PR Newswire.
All rights reserved
. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events2
. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.3
. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 20124
. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 20125
. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter6
. CryoLife Reports Record Quarterly Revenues in First Quarter of 20127
. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results8
. Luminex Corporation Reports First Quarter 2012 Results9
. Hospira Reports First-Quarter 2012 Results10
. Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel11
. The Female Health Company Reports Second Quarter Operating Results